Type 2 myofiber vulnerability is also a known pathological feature and therapeutic target in Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), where the focus is on a selective fast myosin inhibition to protect vulnerable fibers from mechanical stress. This evidence concerns the gene MYH14 and Becker muscular dystrophy.